Priced at $16 for a $150M Nasdaq debut
BlossomHill Therapeutics priced its IPO at $16 a share, raising $150 million with J.P. Morgan and Leerink leading the book. A deal that size for a precision oncology developer is a real test of how far the reopened biotech window extends.
Source: SEC filing
